INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a ma…
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a ma…